Cognizant Joins Industry Standards Group, Align Biopharma
 |
Cognizant, has joined Align BiopharmaTM, an industry standards group made up of more than 20 leading pharmaceutical companies and technology and service providers that are dedicated to making it faster and easier for healthcare professionals to connect with the life sciences industry. A fast-growing influencer in the industry whose aim is to create and implement open technology standards, Align Biopharma’s members are dedicated to making it easier for healthcare professionals (HCPs) to connect digitally with life sciences companies.
In addition to life sciences companies, Align Biopharma members include technology providers, Adobe, Exostar, Gigya, Janrain, and Okta, and service providers including Cognizant among others. These leading companies are helping to define and review Align Biopharma’s open technology standards to ensure broad industry adoption.
“Align Biopharma has seen an overwhelming response from across the industry,” said Henry Levy, President, Align Biopharma. “It’s clear there is a significant opportunity to improve the digital experience for healthcare professionals. We’re attracting the best experts that are shaping the standards to simplify how HCPs get the important treatment information they need.”
“As life sciences companies focus on digital transformation, technology standards are important to enable efficient information sharing across systems and platforms,” said Bhaskar Sambasivan, Senior Vice President and Global Head of Life Sciences, Cognizant. “We look forward to contributing to this important industry initiative that will make it easier for life sciences companies to collaborate with healthcare professionals and help improve patient care.”
Align Biopharma’s first standard is for identity management. Expected to be available in summer 2017, the standard defines the technical requirements for solutions that provide a single sign-on service for HCPs. Align Biopharma has also begun development of its second standard for consent and preference management, which will enable consistency in how healthcare professionals specify communication preferences with each life sciences company. Align Biopharma expects to post its consent and preference management standard for public review and input later this year.
For more information, click here.